The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for certain activity generated through this link. Prices displayed are informational.

Spyre Therapeutics Inc. (NASDAQ:SYRE) is one of the best high short interest stocks with highest upside potential. On May 5, Spyre Therapeutics reported a strong Q1 2026, supported by a public offering that resulted in $1.2 billion in pro forma cash, providing a financial runway into late 2029. While R&D expenses rose to $60.4 million due to clinical trial advancements, the company maintained its strategic focus on developing long-acting antibodies for inflammatory bowel and rheumatic diseases.

The company achieved significant clinical progress, notably reporting positive Phase 2 induction data for SPY001 in ulcerative colitis. With the SKYWAY rheumatoid arthritis sub-study now over-enrolled and timelines accelerated, Spyre remains on track to deliver six proof-of-concept readouts across its primary clinical trials throughout 2026.

Looking ahead, management is prioritizing the ongoing enrollment of its IBD combination therapies in the SKYLINE trial. By focusing on these differentiated pipeline assets, Spyre Therapeutics Inc. (NASDAQ:SYRE) aims to redefine current standards of care while executing a disciplined capital strategy to support long-term growth.

Spyre Therapeutics Inc. (NASDAQ:SYRE) is a US biotechnology company focused on developing medicines for people living with inflammatory bowel disease and rheumatic diseases. It develops advanced antibodies engineered for prolonged activity and formulated for delivery as monotherapies.

While we acknowledge the potential of SYRE as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

READ NEXT: 33 Stocks That Should Double in 3 Years and Cathie Wood 2026 Portfolio: 10 Best Stocks to Buy. 

Disclosure: None. Follow Insider Monkey on Google News.